Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Spatio-temporal changes in SDG under multi-scenario spatio-temporal scenarios. by Bao Zhou (20670850)

Subjects:

Change in the genotypes of <i>ATM</i>, <i>ERCC1</i>, and <i>XRCC1</i>. by Hao Deng (409186)

“…As CWP progressed, the CC and CA genotypes of <i>ERCC1</i> rs3212986 decreased and increased significantly, respectively. …”

Anxiolytic (N05B) prescribing changes from 2014 to 2022. by Dainty Ei (22265317)

Antidepressant (N06A) prescribing changes from 2014 to 2022. by Dainty Ei (22265317)

Changes in the respiration rates of seeds stored under different conditions. by Junming Zhang (5446787)

DALYs and ASDR of thyroid cancer in 2021, and their average annual percentage changes from 1990 to 2021. by Mengjuan Ding (21560393)

DALYs and ASDR of larynx cancer in 2021, and their average annual percentage changes from 1990 to 2021. by Mengjuan Ding (21560393)

DALYs and ASDR of nasopharynx cancer in 2021, and their average annual percentage changes from 1990 to 2021. by Mengjuan Ding (21560393)

Changes in inflammatory cytokine levels compared with baseline values in all patients over time. by Jia Song (495396)

Changes in sRAGE levels in BALF after 120 consecutive days of CS exposure. by Yue He (385239)

Subjects:

Control (Ctrl) STZ mice show changes in glomerular morphology. by Andrey V. Cybulsky (4007012)

Changes in bacterial concentration and monomeric urease activity over time. by Xiaoyan Ding (291429)

HFD changes lysosomal activity. by Tong Yue (6033305)

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Changes in continuous sleep measures from pre (t1) to post (t2) intervention. by Anton Kurapov (11346019)

Changes in mental health symptoms after the sleep intervention (n = 160 completers). by Anton Kurapov (11346019)

Change in maternal characteristics during 2003–2017, HSJ and control. by Eva Rydahl (6260771)

Subjects: